Velarion · Company Intelligence
CompBrief
Fiscal year 2025

Adam Grossman — FY2025 total compensation $10,237,326

Adam Grossman is President, Chief Executive Officer and Director of Adma Biologics, Inc. (ADMA). The company reported total compensation of $10,237,326 for fiscal year 2025.

01

Fiscal year 2025 compensation

Salary$925,000
Bonus$0
Stock awards$4,049,994
Option awards$4,049,998
Non-equity incentive plan$1,156,250
Pension and non-qualified deferred compensation$0
All other compensation$56,084
Total$10,237,326

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.

Cited to the compensation disclosure Adma Biologics, Inc. filed April 15, 2026, accession 0001140361-26-014799.

03

Peer context

Peer-group chief executive median$9,300,485
Difference from that median$936,841
Percentile within the disclosed peer group57th
Peers with a disclosed figure20

Medians and percentiles are computed across the peer group Adma Biologics, Inc. discloses in its own compensation disclosure.

04

The other named executive officers of Adma Biologics, Inc.

Named executive officerRoleFY2025 total
Adam Grossman this pagePresident, Chief Executive Officer and Director$10,237,326
Kaitlin KestenbergChief Operating Officer & Senior Vice President, Compliance$3,488,647
Brad TadeFormer Executive Vice President and Chief Financial Officer$2,823,630
Paul KohlerCurrent Chief Financial Officer and Treasurer$2,296,949

The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Adma Biologics, Inc. compensation brief.

05

The company page

Adam Grossman's compensation sits inside Adma Biologics, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.

The Adma Biologics, Inc. (ADMA) compensation brief